Next Article in Journal
The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration
Previous Article in Journal
Peptide Vaccines for Hypertension and Diabetes Mellitus
Article Menu

Export Article

Open AccessArticle
Vaccines 2014, 2(4), 841-853; doi:10.3390/vaccines2040841

CD137 Enhancement of HPV Positive Head and Neck Squamous Cell Carcinoma Tumor Clearance

1
Cancer Biology Research Center, Sanford Research, Sioux Falls, SD 57104, USA
2
Sanford Health, 2301 East 60th Street North, Sioux Falls, SD 57104, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 24 October 2014 / Revised: 12 November 2014 / Accepted: 21 November 2014 / Published: 10 December 2014
View Full-Text   |   Download PDF [344 KB, uploaded 10 December 2014]   |  

Abstract

Standard-of-care cisplatin and radiation therapy (CRT) provides significant tumor control of human papillomavirus (HPV)-mediated head and neck squamous cell carcinomas (HNSCCs); this effectiveness depends on CRT-mediated activation of the patient’s own immune system. However, despite good survival, patients suffer significant morbidity necessitating on-going studies to define novel therapies that alleviate this burden. Given the role of the immune system in tumor clearance, immune modulation may further potentiate the CRT-activated response while potentially decreasing morbidity. CD137, an inducible cell surface receptor found on activated T cells, is involved in differentiation and survival signaling in T cells upon binding of its natural partner (CD137L). A number of studies have shown the effectiveness of targeting this immune-stimulatory pathway in regards to tumor clearance. Here, we test its role in HPV+ HNSCC tumor clearance using a previously characterized mouse model. We show that amplification of this stimulatory pathway synergizes with CRT for enhanced tumor clearance. Interestingly, tumor clearance is further potentiated by local tumor cell expression of CD137L. View Full-Text
Keywords: CD137; immune; HPV; mouse; squamous CD137; immune; HPV; mouse; squamous
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lucido, C.T.; Vermeer, P.D.; Wieking, B.G.; Vermeer, D.W.; Lee, J.H. CD137 Enhancement of HPV Positive Head and Neck Squamous Cell Carcinoma Tumor Clearance. Vaccines 2014, 2, 841-853.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top